Received Mar 9, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TDAP | TDAP (BOOSTRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | UNK | SYR |
Intramuscular formulation administered by other route; This non-serious case was reported by a consumer via call center representative and described the occurrence of intramuscular formulation administered by other route in a male patient who received DTPa (Reduced antigen) (Boostrix) for prophylaxis. On an unknown date, the patient received Boostrix. On an unknown date, an unknown time after receiving Boostrix, the patient experienced intramuscular formulation administered by other route (Verbatim: Intramuscular formulation administered by other route). The outcome of the intramuscular formulation administered by other route was not applicable. Additional Information: GSK Receipt Date:27-FEB-2026 The Boostrix was administered to the patient intravenously rather than intramuscularly. The batch number was not provided and the request for the information has been made.